Cite
HARVARD Citation
Ascierto, P. et al. (2020). Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. European journal of cancer. pp. 33-44. [Online].